<DOC>
	<DOCNO>NCT01113281</DOCNO>
	<brief_summary>Goal VPM development recombinant urease C-deficient listeriolysin express BCG vaccine strain ( VPM1002 ) safe , well tolerate efficacious vaccine tuberculosis ( TB ) resident endemic area person risk non-endemic area . The new vaccine least potent current strain safer BCG ( Kaufmann , 2007a ; Grode et al. , 2005 ) . The vaccine formulate live lyophilised bacteria re-suspended intradermal injection . The precede clinical trial 80 volunteer Germany indicate immunogenicity safety sufficient proceed clinical development . Hence , current study commence South Africa , country highly endemic tuberculosis . 24 volunteer randomly allocate 4 group 6 adult healthy volunteer .</brief_summary>
	<brief_title>Dose-Escalation Study Safety Immunogenicity VPM1002 Comparison BCG Healthy Volunteers South Africa</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult volunteer 18 45 year age Volunteers must use acceptable contraception avoid pregnancy duration study ( 6 month ) Healthy ( medical history , physical examination , vital sign , ECG laboratory test screen ) No sign active latent tuberculosis infection BMI 19 33 kg/m2 Subjects must able willing comply study protocol , available willing complete study measurement sign Informed Consent form approve Ethics Committee . Reachable phone whole study period ( approximately 6 month ) . Negative test HIV1 HIV2 , hepatitis B surface antigen antibody hepatitis C virus . No anamnestic evidence primary secondary immunodeficiency . No skin eczema lesion intend injection site . No anamnestic predisposition scar badly keloid formation . No vaccination eight week current study . No participation another clinical trial within 3 month study vaccination 6 month current study . No prior participation TB vaccine trial . Able willing abstain strenuous physical exercise 24 hour screen examination , 24 hour vaccination History prior TB disease History anaphylaxis severe allergic reaction Known allergy component investigational reference product know history severe skin reaction Tuberculin test Presence person household volunteer active tuberculosis disease TuberculinPPDinvivotest equal 10 mm baseline systemic disorder could interfere interpretation study result compromise health volunteer BCGvaccination 10 year study vaccination Acute fever fever last 7 day dose Any malignant condition Concomitant treatment medication may affect immune function 3 month study vaccination 6 month current study . No oral antibiotic 14 day study vaccination injectable antibiotic 28 day prior vaccination . Treatment blood product past 6 month end study . Any clinically significant laboratory abnormality screen blood sample . A history drug alcohol abuse Positive test drug abuse urine test screen Blood donation non studyrelated purpose within 3 month entire duration study Clinically relevant result sonographic liver image Professional regular contact live animal food production</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Live Vaccine</keyword>
	<keyword>rBCG</keyword>
</DOC>